Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- XTLB
- Price
- 1.05
- Stock movement up
- +0.08 (8.11%)
- Company name
- XTL Biopharmaceuticals Ltd ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 9.25M
- Ent value
- 12.00M
- Price/Sales
- 12.51
- Price/Book
- 1.70
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -11.06%
- 1 year return (CAGR)
- -85.50%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
XTLB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 12.51 |
| Price to Book | 1.70 |
| EV to Sales | 16.21 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 8.81M |
| EPS (TTM) | -1.00 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 740.00K |
| Gross profit (TTM) | 76.00K |
| Operating income (TTM) | -2.81M |
| Net income (TTM) | -1.77M |
| EPS (TTM) | -1.00 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 10.27% |
| Operating margin (TTM) | -379.59% |
| Profit margin (TTM) | -238.78% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 371.00K |
| Net receivables | 99.00K |
| Total current assets | 1.34M |
| Goodwill | 3.19M |
| Intangible assets | 3.82M |
| Property, plant and equipment | 0.00 |
| Total assets | 8.55M |
| Accounts payable | 196.00K |
| Short/Current long term debt | 138.00K |
| Total current liabilities | 2.21M |
| Total liabilities | 3.12M |
| Shareholder's equity | 5.43M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -32.51% |
| Return on Assets | -20.67% |
| Return on Invested Capital | -31.71% |
| Cash Return on Invested Capital | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.89 |
| Daily high | 1.09 |
| Daily low | 0.89 |
| Daily Volume | 268K |
| All-time high | 2284.00 |
| 1y analyst estimate | 30.00 |
| Beta | 0.78 |
| EPS (TTM) | -1.00 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| XTLB | S&P500 | |
| Current price drop from All-time high | -99.95% | -0.89% |
| Highest price drop | -99.97% | -19.00% |
| Date of highest drop | 31 Dec 2025 | 8 Apr 2025 |
| Avg drop from high | -99.77% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
9.25M
Marketcap category
Small-cap
Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Employees
10
Website
Investor relations
-
SEC filings
CEO
Joshua Levine
Country
USA
City
Raanana
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Breaking news and real-time stock market updates from Seeking Alpha. Check out the latest investing news and financial headlines.
March 7, 2017
iO Charts is a Seeking Alpha partnerNext page